,27, 28, 29 So far, immunotherapies targeting PD-(L)1 have demonstrated OS benefits in patients with platinum-refractory or platinum-eligible advanced HNSCC.30, 31, 32. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.